Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Lexeo Therapeutics Inc (LXEO)

138 + Investors. Track Smart Money conviction in LXEO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -4
Streak
1Q ▼
Buyers last Q
55%

Smart Money Signals — LXEO

Based on 140 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their LXEO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (97% of max)

97% of all-time peak
140 hedge funds hold LXEO right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +61% more funds vs a year ago

fund count last 6Q
+53 new funds entered over the past year (+61% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 55% buying

79 buying65 selling
Last quarter: 79 funds bought or added vs 65 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-25 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 16 → 27 → 47 → 22. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔄

Mostly new holders — 44% entered in last year

■ 23% conviction (2yr+) ■ 33% medium ■ 44% new
Only 32 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💎

Buying through price weakness — shares +5%, value -40%

Value
-39%
Shares
+4%
Last quarter: funds added +5% more shares while total portfolio value only changed -40%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

17 → 16 → 27 → 47 → 22 new funds/Q
New funds entering each quarter: 16 → 27 → 47 → 22. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
📊

Mixed cohorts — 19% veterans, 52% new entrants

■ 19% veterans ■ 29% 1-2yr ■ 52% new
Of 143 current holders: 27 (19%) held 2+ years, 41 held 1–2 years, 75 (52%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.
✅

Strong quality — 34% AUM from major funds

34% from top-100 AUM funds
38 of 139 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.9
out of 10
Moderate Exit Risk
Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — LXEO

In 2026 Q1, 79 hedge funds were net buyers of LXEO (22 opened a new position, 57 added to an existing one), while 65 reduced or exited (39 trimmed, 26 sold completely) — a 55% buyer ratio, indicating a slight buying edge. 34% of total institutional value in LXEO is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: -4 funds (more exits than new entries). Total institutional holders: 140.

Hedge Fund Ownership: LXEO

How many hedge funds hold LXEO — quarterly history vs. share price
Quarterly hedge fund ownership of LXEO vs. share price

Market Analysis: LXEO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: LXEO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Lexeo Therapeutics Inc (LXEO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much LXEO has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 47d ago
LXEO
+4.0%
XLV
+5.5%

LXEO outperformed XLV by -1.5% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 2d ago
LXEO
+0.0%
XLV
+0.0%

Since the filing became public, LXEO outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

20 top-rated funds 1 high-conviction
Consensus
5.7
/ 10
breadth
×
Elite
1.5
/ 10
conviction
Hedge Fund Positioning: LXEO
2026 Q2 Stats Unlock in 3 days 138 + Investors

Track Smart Money conviction in LXEO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 138 144 -4.17%
13F Shares 80M 76M 4.5%
Total Value $459M $759M -39.54%
New Positions 20 47 -27
Increased Positions 57 59 -2
Closed Positions 26 13 +13
Reduced Positions 37 26 +11
Total Calls 3 1 200.0%
Total Puts 1 1 -
PUT/CALL Ratio 0.33 1.0 Bullish

Statistics: LXEO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

138 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LXEO. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 LXEO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Caxton Corp 4.26% 16,962 $79K
2 Affinity Asset Advisors, LLC 1.22% 5,807,611 $27.0M
3 Spruce Street Capital LP 0.85% 928,593 $4.3M
4 Montanova Capital, LLC 0.54% 6,384,200 $29.7M
5 Frazier Life Sciences Management, L.P. 0.49% 4,824,725 $22.5M
6 Vestal Point Capital, LP 0.47% 4,320,000 $20.1M
7 683 Capital Management, LLC 0.43% 1,875,000 $8.7M
8 Paradigm Biocapital Advisors LP 0.36% 4,175,382 $19.4M
9 Orbimed Advisors LLC 0.34% 3,947,850 $18.4M
10 DAFNA Capital Management LLC 0.33% 377,059 $1.8M
11 ADAR1 Capital Management, LLC 0.33% 1,565,950 $7.3M
12 Ikarian Capital, LLC 0.26% 513,011 $2.4M
13 Ra Capital Management, L.P. 0.20% 5,000,000 $23.3M
14 Nantahala Capital Management, LLC 0.20% 1,300,000 $6.1M
15 Verdad Advisers, LP 0.14% 30,591 $142K
16 Spark Investment Management LLC 0.14% 15,000 $70K
17 Privium Fund Management B.V. 0.13% 155,000 $722K
18 Palumbo Wealth Management LLC 0.11% 114,743 $534K
19 Virtus Investment Advisers, LLC 0.08% 74,874 $349K
20 Avoro Capital Advisors LLC 0.06% 1,489,189 $6.9M
21 Woodline Partners LP 0.04% 2,500,532 $11.6M
22 Hennion & Walsh Asset Management, Inc. 0.04% 265,697 $1.2M
23 Dynamic Technology Lab Private Ltd 0.03% 32,651 $152K
24 Burkehill Global Management, LP 0.02% 125,000 $582K
25 Balyasny Asset Management L.P. 0.01% 2,412,742 $11.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Lexeo Therapeutics Inc (LXEO)

What does the Smart Money Trend signal show for LXEO?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their LXEO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for LXEO?

Slight buying edge — 55% buying: Last quarter: 79 funds bought or added vs 65 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for LXEO holders?

Strong quality — 34% AUM from major funds: 38 of 139 holders rank in the top 100 by AUM, accounting for 34% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held LXEO?

Mostly new holders — 44% entered in last year: Only 32 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Lexeo Therapeutics Inc (LXEO) following the 2026 Q2 hedge fund 13F filings?

As of today, LXEO has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), LXEO has gained +4.0% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →